A newly engineered, ultra-small CRISPR gene-editing system has demonstrated dramatically improved efficiency in human cells, paving the way for therapies that could be delivered directly inside the body to treat a range of diseases.
Researchers have successfully enhanced a naturally compact enzyme called Al3Cas12f, making it both small enough for advanced delivery methods and powerful enough for effective genome editing. This addresses a critical bottleneck in the field, as the most commonly used CRISPR proteins are too large to fit into targeted viral delivery vectors, limiting treatments to cells that must be extracted, edited in a lab, and reinfused. The enhanced variant, dubbed Al3Cas12f RKK, boosted editing efficiency from less than 10% to over 80% at tested genetic targets, with one region reaching 90%.
The team discovered that the original Al3Cas12f enzyme has a uniquely stable structure, forming a tightly connected complex that remains ready for action inside cells. "Compared to the others we looked at, Al3Cas12f basically comes preassembled and ready to go shortly after its pieces are produced," said David Taylor, Ph.D., the corresponding author. By engineering the RKK variant, the scientists amplified this inherent stability and effectiveness, creating a tool that performed reliably in human cells, including those derived from a patient with leukemia.
The implications for patients are significant. This miniature system is designed to fit inside adeno-associated virus (AAV) vectors, which are a leading method for delivering genetic medicine precisely to specific organs or tissues within the body. This could potentially expand CRISPR-based treatments beyond blood disorders to conditions like certain cancers, amyotrophic lateral sclerosis (ALS), and atherosclerosis, where targeted, in-body editing is essential.
The research team now plans to test the performance of the Al3Cas12f RKK system when packaged into AAV vectors, a crucial next step toward clinical development. If successful, this compact technology could bring direct, in vivo gene-editing therapies for many stubborn diseases closer to reality, marking a hopeful advance in the quest for precise and accessible genetic medicine.